Contact information

Prof. Dr. med. Dr. rer. nat. Sandrine Sander

Adaptive Immunity and Lymphoma

German Cancer Research Center (DKFZ)

Im Neuenheimer Feld 280

69120 Heidelberg


National Center for Tumor Diseases (NCT) Heidelberg

Im Neuenheimer Feld 460

69120 Heidelberg



Academic education

2005 - 2009 International Graduate School in Molecular Medicine Ulm, Ulm University
1997 - 2004 Medical School, Ulm University


Scientific degrees

03/2009 PhD, Institute of Physiological Chemistry, Ulm University. Advisor: Prof. T. Wirth (Grade: Summa cum laude)
11/2005 MD, Department of Internal Medicine III, Ulm University. Advisor: Prof. S. Stilgenbauer (Grade: Magna cum laude)


Scientific career

09/2023 - present W3 Professor in Translational and Experimental Oncology, University of Greifswald
2015 - 2023 Max Eder research group leader at the German Cancer Research Center (DKFZ)/ National Center for Tumor Diseases (NCT) Heidelberg
2012 - 2015 Senior Scientist, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Immune Regulation and Cancer, Advisor: Prof. K. Rajewsky
2009 - 2011 Postdoctoral Fellow, Harvard Medical School, Genetics of Cancer and Immunodeficiency, Immune Disease Institute, Advisor: Prof. K. Rajewsky


Honors/ Awards/ Memberships

2017 Franziska Kolb Prize for Leukemia Research, University of Ulm
2015 Max Eder fellowship of the Deutsche Krebshilfe
2013 Curt Meyer Memorial Prize, Berlin Cancer Society
2010 Fellowship in the Career Development Program of The Leukemia & Lymphoma Society, USA
2010 Postdoctoral fellowship of the Deutsche Forschungsgemeinschaft (relinquished)
2008 - present Member of the American Association for Cancer Research
2008 Doctoral Student Award, International Graduate School in Molecular Medicine Ulm
2005 PhD student fellowship, International Graduate School in Molecular Medicine Ulm


  • Concomitant Cytotoxic Effector Differentiation of CD4+ and CD8+ T Cells in Response to EBV-Infected B Cells

    Most people infected by EBV acquire specific immunity, which then controls latent infection throughout their life. Immune surveillance of EBV-infected cells by cytotoxic CD4+ T cells has been recognized; however, the molecular mechanism of generating cytotoxic effector T cells of the CD4+ subset…

  • An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities

    Based on gene expression profiles, diffuse large B-cell lymphoma (DLBCL) is subdivided into germinal center B-cell–like (GCB) and activated B-cell–like (ABC) DLBCL. Two of the most common genomic aberrations in ABC-DLBCL are mutations in MYD88 as well as BCL2 copy-number gains. Here, we employ…

  • Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma

    Aberrant activity of the glycoprotein 130 130/JAK/STAT3 (gp130/JAK/STAT3) signaling axis is a recurrent event in inflammation and cancer. In particular, it is associated with a wide range of hematological malignancies, including multiple myeloma and leukemia. Novel targeted therapies have only been…

  • BCR-dependent lineage plasticity in mature B cells

    B2 cells engage in classical antibody responses, whereas B1 cells are considered carriers of innate immunity, biased toward recognizing epitopes present on the surfaces of common pathogens and self antigens. To explore the role of B cell antigen receptor (BCR) specificity in driving B1 cell…